Filip Dubovsky - Mar 7, 2024 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President, R&D
Signature
/s/ Mark J. Casey, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Mar 7, 2024
Transactions value $
-$52,689
Form type
4
Date filed
3/11/2024, 09:40 PM
Previous filing
Mar 26, 2024
Next filing
Mar 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise +19.4K +36.15% 73.2K Mar 7, 2024 Direct F1
transaction NVAX Common Stock Tax liability -$52.7K -9.39K -12.83% $5.61 63.8K Mar 7, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -19.4K -100% $0.00* 0 Mar 7, 2024 Common Stock 38.9K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date